Company news

Keymed Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 2, 2026

Voluntary announcement - share purchase pursuant to the 2022 restricted share unit scheme

October 29, 2026

Inside information announcement-(1) update on product revenue for the first three quarters of 2026 and (2) national medical products administration approves the new indication marketing application for Stapokibart for the treatment of moderate-to-severe atopic dermatitis in adolescents

October 15, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 5, 2026

2026 Interim report

September 22, 2026

Keymed Biosciences Announces 2026 H1 Results and Business Updates

August 20, 2026

Keymed Biosciences Announces 2025 Annual Results and Business Updates

March 26, 2026

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

August 27, 2025

Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine

June 16, 2025

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

June 11, 2025

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

April 25, 2025

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

April 24, 2025

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

April 5, 2025

Keymed Biosciences Announces Annual Results of 2024

March 26, 2025

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

February 10, 2025

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

December 24, 2024

License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed

March 30, 2023

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

March 16, 2023

Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect

March 7, 2022

Keymed Bio Joins Hang Seng Family of Indexes

February 18, 2022

Decks